LifeStance Health Group (NASDAQ:LFST) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• LifeStance reported quarterly EPS of $0.06, beating estimates by $0.02, while revenue rose 25.3% year over year to $455.9 million and exceeded forecasts.
• The company raised its 2026 revenue outlook to $1.741–$1.761 billion and adjusted EBITDA guidance to $242–$250 million; quarterly adjusted EBITDA climbed 70% to $68 million.
• Growth was supported by higher visit volume and an expanding clinician base, but the EHR rollout is expected to weigh on 2027 revenue growth by 1–2 percentage points and incur $20–$30 million in implementation costs.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) issued its earnings results on Thursday. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.02, Zacks reports. The company had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The firm's revenue for the quarter was up 25.3% compared to the same quarter last year.

Here are the key takeaways from LifeStance Health Group's conference call:

• Third-quarter revenue rose 25% to $456 million, driven by 17% growth in visit volume and a 7% increase in revenue per visit. Adjusted EBITDA increased 70% to $68 million, a 15% margin for the second consecutive quarter.
• LifeStance raised its full-year 2026 guidance: revenue to $1.741 billion–$1.761 billion and Adjusted EBITDA to $242 million–$250 million. The midpoint implies 23% revenue growth and roughly 300 basis points of year-over-year margin expansion.
• The clinician base grew 11% to 8,863, with 321 net additions in the quarter; management cited strong recruiting and stable retention. Visits per average clinician rose 5% year over year, which executives attributed partly to improved patient engagement.
• Specialty services revenue is expected to grow about 40% in 2026 to roughly $70 million, with management expecting a similar growth rate next year. The company is gradually expanding TMS and SPRAVATO, while citing positive outcomes data and opportunities to discuss coverage and reimbursement with payers.
• The new EHR rollout is expected to reduce 2027 revenue growth by approximately 1–2 percentage points, putting growth toward the lower end of LifeStance’s long-term mid-teens range. Management also previously estimated implementation costs of $20 million–$30 million; the phased rollout is expected to be completed by year-end 2027.

LifeStance Health Group Trading Up 2.5%

LFST traded up $0.34 on Friday, hitting $13.77. The company had a trading volume of 4,924,487 shares, compared to its average volume of 3,459,394. The company's fifty day moving average price is $12.62 and its 200 day moving average price is $9.49. LifeStance Health Group has a 1 year low of $5.87 and a 1 year high of $15.66. The company has a current ratio of 1.44, a quick ratio of 1.38 and a debt-to-equity ratio of 0.17. The firm has a market cap of $5.26 billion, a P/E ratio of 72.47 and a beta of 1.35.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 11th. Zacks Research lowered shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Wall Street Zen cut LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 5th. Finally, KeyCorp increased their price objective on LifeStance Health Group from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $13.75.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

Insiders Place Their Bets

In related news, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the transaction, the chief technology officer owned 247,446 shares of the company's stock, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Lisa K. Miller sold 47,912 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares of the company's stock, valued at $3,051,985.65. This trade represents a 14.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,777,580 shares of company stock valued at $146,433,781 over the last 90 days. 3.50% of the stock is owned by company insiders.

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.